Therapeutic effects of direct renin inhibitor in end stage kidney disease patients with maintenance hemodialysis

Therapeutic effects of direct renin inhibitor in end stage kidney disease patients with maintenance hemodialysis - Therapeutic effects of direct renin inhibitor in end stage kidney disease patients with maintenance hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003551

Enrollment

Registered

2010-05-01

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension,End stage kidney disease

Interventions

Angiotensin receptor blocker(ARB) Direct renin inhibitor(DRI)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: end stage kidney disease patients with maintenance hemodialysis take regular-dose ARB by mouth, and their predialysis blood pressure are from 130 to 170mmHg.

Exclusion criteria

Exclusion criteria: end stage kidney disease patients with maintenance hemodialysis take ACE inhibitore by mouth. The assay of HANP are more than 200 and cardiothorakic ratio more than 55%. Inappropriate condition for the patient. Patients,who refuse informed consent.

Design outcomes

Primary

Measure	Time frame
Predialysis blood pressure	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026